MX2019003733A - Tratamiento de cancer de prostata. - Google Patents

Tratamiento de cancer de prostata.

Info

Publication number
MX2019003733A
MX2019003733A MX2019003733A MX2019003733A MX2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A
Authority
MX
Mexico
Prior art keywords
subject
prostate cancer
methoxyurea
tetrahydrothien
difluorobenzyl
Prior art date
Application number
MX2019003733A
Other languages
English (en)
Spanish (es)
Inventor
Reddy Rajasekhar Vijaykumar
Mark Johnson Brendan
B Maclean David
Seely Lynn
N Mudd Paul Jr
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of MX2019003733A publication Critical patent/MX2019003733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2019003733A 2016-09-30 2017-09-29 Tratamiento de cancer de prostata. MX2019003733A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402150P 2016-09-30 2016-09-30
US201662402004P 2016-09-30 2016-09-30
PCT/EP2017/074849 WO2018060463A2 (en) 2016-09-30 2017-09-29 Treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX2019003733A true MX2019003733A (es) 2019-09-26

Family

ID=60915459

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003733A MX2019003733A (es) 2016-09-30 2017-09-29 Tratamiento de cancer de prostata.
MX2023001468A MX2023001468A (es) 2016-09-30 2019-03-29 Tratamiento de cancer de prostata.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001468A MX2023001468A (es) 2016-09-30 2019-03-29 Tratamiento de cancer de prostata.

Country Status (21)

Country Link
US (8) US10449191B2 (https=)
EP (2) EP3518932B1 (https=)
JP (1) JP7062673B2 (https=)
CN (1) CN110248661A (https=)
AU (2) AU2017334035B2 (https=)
BR (1) BR112019006228A2 (https=)
CA (1) CA3038875A1 (https=)
DK (1) DK3518932T3 (https=)
ES (1) ES3002857T3 (https=)
FI (1) FI3518932T3 (https=)
HR (1) HRP20241740T1 (https=)
HU (1) HUE070578T2 (https=)
IL (3) IL308528A (https=)
LT (1) LT3518932T (https=)
MA (1) MA46361A (https=)
MX (2) MX2019003733A (https=)
NZ (1) NZ752918A (https=)
PL (1) PL3518932T3 (https=)
PT (1) PT3518932T (https=)
SI (1) SI3518932T1 (https=)
WO (1) WO2018060463A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
JP2022551316A (ja) * 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022087593A1 (en) * 2020-10-20 2022-04-28 Baylor College Of Medicine Multiplex metabolic markers in plasma for early detection of african american prostrate cancer
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023152611A1 (en) * 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
KR20030005205A (ko) 2000-02-29 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 유도체의 제조 방법
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US7569570B2 (en) 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
BRPI0307786B8 (pt) 2002-02-26 2021-05-25 Astrazeneca Ab composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
AU2004257639B2 (en) 2003-07-07 2011-01-06 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
EP2155194B1 (en) 2007-04-06 2015-01-21 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
US10821152B2 (en) 2014-08-26 2020-11-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
US20180044977A1 (en) 2016-08-12 2018-02-15 Raynor Mfg. Co. Rolling door construction for controlling air leakage
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis

Also Published As

Publication number Publication date
EP3518932B1 (en) 2024-11-13
PL3518932T3 (pl) 2025-04-07
CA3038875A1 (en) 2018-04-05
US10449191B2 (en) 2019-10-22
US20250082632A1 (en) 2025-03-13
EP3518932A2 (en) 2019-08-07
WO2018060463A3 (en) 2018-05-11
US12097198B2 (en) 2024-09-24
JP7062673B2 (ja) 2022-05-06
MX2023001468A (es) 2023-03-03
US20200129507A1 (en) 2020-04-30
IL300071A (en) 2023-03-01
IL265697A (en) 2019-05-30
EP4520398A3 (en) 2025-04-02
US20220401443A1 (en) 2022-12-22
US20250057839A1 (en) 2025-02-20
IL265697B2 (en) 2023-07-01
US20190224196A1 (en) 2019-07-25
MA46361A (fr) 2021-03-31
IL265697B1 (en) 2023-03-01
SI3518932T1 (sl) 2025-03-31
US11583526B2 (en) 2023-02-21
US20210205303A1 (en) 2021-07-08
HUE070578T2 (hu) 2025-06-28
US12336990B2 (en) 2025-06-24
DK3518932T3 (da) 2025-01-27
JP2019529574A (ja) 2019-10-17
AU2023201047B2 (en) 2025-04-03
EP4520398A2 (en) 2025-03-12
BR112019006228A2 (pt) 2019-06-18
IL308528A (en) 2024-01-01
US20240358700A1 (en) 2024-10-31
AU2017334035B2 (en) 2022-11-24
FI3518932T3 (fi) 2025-02-03
AU2023201047A1 (en) 2023-03-23
WO2018060463A2 (en) 2018-04-05
CN110248661A (zh) 2019-09-17
US10786501B2 (en) 2020-09-29
US12144809B1 (en) 2024-11-19
HRP20241740T1 (hr) 2025-02-28
PT3518932T (pt) 2025-01-16
AU2017334035A1 (en) 2019-05-16
LT3518932T (lt) 2025-02-10
US20250332166A1 (en) 2025-10-30
ES3002857T3 (en) 2025-03-07
NZ752918A (en) 2022-09-30

Similar Documents

Publication Publication Date Title
MX2019003733A (es) Tratamiento de cancer de prostata.
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
RU2016129953A (ru) Фармацевтические комбинации
HRP20220718T1 (hr) Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
NZ736048A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
JOP20240237A1 (ar) مركبات أريل غير متجانسة لمعالجة الألم
RU2017102319A (ru) Прерывистое введение ингибитора mdm2
JOP20240235A1 (ar) مركبات أريل غير متجانسة لمعالجة الألم
MX2013010770A (es) Tratamiento de tumores solidos.
MX374724B (es) Derivados de carbazol.
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
JOP20210320A1 (ar) طرق علاج السرطان باستخدام مثبطات prmt5
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla